Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Genmab (GMAB) and Incyte (INCY) will collaborate on a Phase 1/2 trial for a combination therapy targeting KRAS G12D-mutated metastatic colorectal cancer. Genmab's petosemtamab and Incyte's INCB161734 will be tested with standard chemotherapy. Incyte will supply the drug and co-fund the trial, while Genmab leads the study.

Genmab and Incyte will collaborate on a Phase 1/2 trial of petosemtamab with Incyte's KRAS G12D inhibitor and chemotherapy for metastatic colorectal cancer. Incyte will co-fund and supply its drug. The study targets a high-need population, with potential for further development if successful.

Incyte (INCY) and Genmab (GMAB) are collaborating on a clinical trial to evaluate Incyte's KRAS G12D inhibitor INCB161734 with Genmab's bispecific antibody petosemtamab and standard chemotherapy for metastatic colorectal cancer with KRAS G12D mutation. The Phase 1/2 study will be co-funded by both companies, with Genmab conducting the trial and Incyte providing the clinical supply of INCB161734. This collaboration aims to address a significant unmet medical need in this patient population.

Incyte (INCY) and Genmab will collaborate on a Phase 1/2 trial for KRAS G12D-mutated metastatic colorectal cancer, combining Incyte's INCB161734 with Genmab's petosemtamab and chemotherapy. Incyte will co-fund and supply the drug, while Genmab will lead the study.

Genmab's stock rose ~10% after its phase 3 trial for ovarian cancer treatment rinatabart sesutecan met primary goals, targeting folate receptor alpha.

Genmab (GMAB) reported positive Phase 3 trial results for rinatabart sesutecan, showing a 71% reduction in disease progression risk. The trial met its primary endpoint, improving progression-free survival over standard chemotherapy. Genmab's stock is trading at $42.78, with a GF Value™ of $36.02, suggesting modest overvaluation. The company has a GF Score™ of 96, reflecting strong profitability and growth.